

# Prevalence and Incidence of Problematic Prescription Opioid Use and Abuse in the United Kingdom and Germany (OXY9504)

**First published:** 30/06/2015

**Last updated:** 30/03/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS10129

### Study ID

17996

### DARWIN EU® study

No

### Study countries

☐ Germany

☐ United Kingdom

### Study status

Finalised

## Research institutions and networks

# Institutions

## Real World Evidence Solutions, IMS Health

☐ France

**First published:** 06/09/2011

**Last updated:** 20/08/2024

**Institution**

**Other**

## Contact details

### Study institution contact

Cooper Andrew [andrew.cooper@mundipharma-rd.eu](mailto:andrew.cooper@mundipharma-rd.eu)

**Study contact**

[andrew.cooper@mundipharma-rd.eu](mailto:andrew.cooper@mundipharma-rd.eu)

### Primary lead investigator

Joseph Kim

**Primary lead investigator**

## Study timelines

### Date when funding contract was signed

Planned: 11/11/2013

Actual: 02/12/2013

---

**Study start date**

Planned: 11/03/2014

Actual: 08/04/2014

---

**Data analysis start date**

Planned: 25/05/2015

---

**Date of final study report**

Planned: 25/05/2016

Actual: 27/06/2016

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Mundipharma Research Ltd

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Drug utilisation

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

Quantify problematic prescription use and abuse of prescription opioids in

Germany and the United Kingdom

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Anatomical Therapeutic Chemical (ATC) code**

(N02A) OPIOIDS

OPIOIDS

---

## **Medical condition to be studied**

Drug abuse

## Population studied

### **Short description of the study population**

Patients with opioids use in the UK and Germany.

---

### **Age groups**

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

### **Estimated number of subjects**

180000

## Study design details

### **Outcomes**

Incidence and 5-year prevalence of problematic prescription use and abuse of prescription opioids from 2008-2012, Characterisation of the abusing and non-abusing population: demographics, drug utilisation.

---

## Data analysis plan

Calculation of incidence rate and 5-year prevalence of problematic use of prescription opioids per molecule from 2008 to 2012.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

Clinical Practice Research Datalink

---

### Data sources (types)

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

Unknown